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for successive administration.
& 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1
l Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3271485; fax: þ86 025 83271485.
Li Ding).
itute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.
Pharmacokinetics of levosulpiride after intramuscular administration 4031. Introduction
Levosulpiride (Fig. 1A), N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-
2-methoxy-5-sulfamoylbenzamide, the levorotatory form of sulpir-
ide enantiomers, is a benzamide derivative, which speciﬁcally
blocks dopamine D2- and D3-receptors both in the central and
peripheral nervous system (CNS and PNS)1,2. Levosulpiride has
therapeutic efﬁcacy in psychiatric disorders like depression,
somatoform disorders, schizophrenia3, dyspepsia and emesis4,5,
vertigo and premature ejaculation6. Compared with the dextro
enantiomer, levosulpiride has stronger pharmacological activities1.
Since metabolic conversion at the chiral center of the drug has
been observed in rats, no marked differences in pharmacokinetic
parameters of the enantiomers has been noted7. Studies suggest
that compared with the enantiomers, lower doses of levosulpiride
can produce identical or even higher efﬁcacy1, greatly diminishing
the occurrence of adverse events8.
Levosulpiride mainly exists in ionic form at physiological pH
because of its pKa. Metabolites found in other species were all
missing in human urine, indicating that the parent drug, rather than
metabolites, plays an extremely important role in drug disposi-
tion9. The bioavailability of sulpiride is about 30% after oral
administration10, probably due to incomplete gastrointestinal
absorption10–13. The value is nearly 100% after intramuscular
(im) administration14,15. Following oral administration, intra-
individual and inter-individual variabilities were high, with a
coefﬁcient of variation for all subjects above 25% in the
pharmacokinetics parameters10,14,16. These differences, most likely
attributable to variations in absorption, could be due to genetic
polymorphisms or ﬂuctuations in gastrointestinal pH. Pharmaco-
kinetics of sulpiride in humans was linear over the test dose range
after im administration15 and oral administration10. Gender dis-
crepancy was also investigated after intravenous (iv) administra-
tion. These results showed that the distribution of sulpiride was
slightly slower, and area under the curve notably higher in male
subjects14.
The aims of this study were to evaluate the pharmacokinetics of
levosulpiride for the ﬁrst time in healthy Chinese volunteers after
im administration of a single 25 mg dose, a single 50 mg dose and
multiple 25 mg doses, and to compare these parameters with those
from Caucasian and Korean populations.Figure 1 Chemical structures of levosulpiride (A) and enalaprilat
(B, IS).2. Materials and methods
2.1. Chemicals and reagents
Levosulpiride (reference standard, purity 100%) was provided by
Shanghai Hotmed Sciences Co., Ltd. (Shanghai, China), and the
internal standard enalaprilat (IS, purity 100%, Fig. 1B) was
purchased from National Institutes for Food and Drug Control
(Beijing, China). The test formulation levosulpiride injections
(25 mg/2 mL, 50 mg/4 mL) were provided by Shanghai Hotmed
Sciences Co., Ltd. (Shanghai, China). Methanol (HPLC-grade)
was obtained from Merck KGaA (Darmstadt, German). Formic
acid and ammonium acetate (analytical grade) were purchased
from Nanjing Chemical Reagent Co., Ltd. (Nanjing, China).
2.2. Subjects
Twelve healthy Chinese volunteers (6 males and 6 females) were
enrolled. All subjects provided written informed consent. All the
experiments were approved by an Independent Ethics Committee
and carried out in accordance with the Declaration of Helsinki and
Good Clinical Practice Guidelines. All the volunteers met the
selection criteria: a body mass index (BMI) between 19 and
24 kg/m2, 18–31 years old, in good health as determined
by screening; laboratory examination (including hematology,
biochemical tests, urine routine tests, and electrocardiogram),
medical history, vital signs and physical examination. The demo-
graphic data for all subjects are given in Table 1. All laboratory
parameters were monitored during screening and after the study.
Vital signs and adverse events were recorded before and throughout
the study.
2.3. Study design
Single-dose pharmacokinetic study was carried out with an open-
label, randomized, 2-way crossover study design. The 12 volun-
teers were randomly allocated to two groups (group 1 and group
2), and each group had 3 males and 3 females. They were required
to fast overnight for at least 10 h, and were given breakfast 1 h
before dose administration. Group 1 received a single im injection
of 25 mg (2 mL) levosulpiride in gluteus muscle, then after a 1-
week washout period, they were given a single im injection of
50 mg (4 mL) levosulpiride. Group 2 were given a 50 mg (4 mL)
dose of levosulpiride, then after a washout period were given a
25 mg (2 mL) dose of levosulpiride. After the single-dose experi-
ments, multi-dose (25 mg dose) pharmacokinetic study was
assessed with im administration of levosulpiride every 12 hours
on the ﬁve consecutive days. In the single-dose studies, a catheter
was placed in the forearm vein, and venous blood samples (4 mL)
were collected in heparinized tubes immediately before and 5, 10,
15, 20, 25, 30, 40 min, 1, 2, 3, 5, 8, 12, 24 and 36 h after each
injection. In the multi-dose study, plasma samples were drawnTable 1 Demographic data for the subjects.
Sex Age
(year)
Weight
(kg)
Height
(cm)
BMI
(kg/m2)
Male 24.871.9 62.576.3 17277 21.271.9
Female 25.374.4 54.375.4 16075 21.371.6
Data are mean7standard deviation. n¼6 for males and females.
C. Gong et al.404prior to the morning injections on day 3, 4, 5 and 5, 10, 15, 20, 25,
30, 40 min, 1, 2, 3, 5, 8, 12, 24 and 36 h after the morning
injections on day 5. Plasma was isolated immediately by centri-
fugation at 4000 rpm for 5 min and stored at 20 1C until
analysis. The light diets were served 4 h and 10 h after the
injections.
2.4. Sample preparation
Samples (blank plasma samples, standard working solutions) were
ﬁrst thawed at ambient temperature and vortex-mixed. An aliquot
of 200 mL plasma was transferred into a centrifuge tube containing
20 mL IS working standard. This was vortex-mixed for 5 s,
followed by addition of 800 mL methanol as protein precipitation
agent. After vortex-mixing for 3 min, this tube was centrifuged for
10 min at 15,600 rpm and supernatant transferred to a sample vial
for analysis. The injection volume was 5 mL.
2.5. Instrumentation
The Agilent series 1200 HPLC system and 6410B mass system
(Agilent Technologies, Palo Alto, CA) included a binary pump,
an autosampler, a temperature controlled column and a triple
quadrupole MS. Chromatographic separation was performed on a
Hanbon Hedera ODS-2 (150 mm 2.1 mm, 5 mm, Hanbon Sci &
Tech Co., Ltd., China) with a gradient elution system of methanol
(A) and water phase (B) (containing 0.002% formic acid and
5 mmol/L ammonium acetate) at a ﬂow rate of 0.4 mL/min. The
mobile phase program was 0–0.5 min: 10% A; 0.5–0.75 min: 10%
A-80% A; 0.75–3 min: 80% A; 3–3.05 min: 80% A-100% A;
3.05–4 min: 100% A; 4–4.25 min: 100% A-10% A; 4.25–8 min:
10% A. The autosampler was maintained at 15 1C, and the column
at 35 1C. Under these conditions, the total run time was 8 min and
the injection volume was 5 mL.
HPLC eluates were analyzed by triple quadrupole mass spectro-
meter, with an electrospray ion source (ESI). The tandem mass
spectrometer was operated in ESI positive mode at a unit
resolution using multiple reaction monitoring (MRM) data acqui-
sition. The monitoring transitions for levosulpiride and the IS were
342.0-112.0 and 349.1-206.1, respectively. The MS conditions
were: fragmentor 120 V, drying gas 12 L/min, drying gas tem-
perature 350 1C, and nebulizer pressure 45 psig. Collision energy
was 25 V for levosulpiride and 15 V for the IS. Data were
collected by using Agilent MassHunter.
2.6. Statistical analysis
All pharmacokinetic calculations of the study were carried out
with the drug and statistics (DAS) 2.1.1 pharmacokinetic program
authorized by the Chinese Pharmacology Society (Beijing, China),
and statistical analyses were performed with SPSS 11.5 (LEAD
Technologies Inc.). Key pharmacokinetic parameters were derived
by noncompartmental methods and then compared by using SPSS
statistical analysis software package. P value of less than 0.05 was
considered statistically signiﬁcant.
Peak plasma concentration at steady state (Cssmax) and time to
peak plasma concentration (Tmax) were taken as the observed data.
DAS was used to calculate the pharmacokinetic parameters,
including Cav, t1/2, DF, area under the concentration–time curve
from time zero to time of the last quantiﬁable concentration
(AUC0 t), area under the concentration–time curve from 0 h to12 h (AUC0τ), area under the concentration–time curve from 0 h
to 12 h at steady state (AUCss), mean residence time (MRT0 t),
apparent volume of distribution (Vz/F), apparent clearance
(CLz/F), and plasma concentration at steady state before injection
on day 5 (Cssmin). R was calculated as AUCss/AUC0τ or Cssmax/
Cmax
17.
The Cmax and AUC values were logarithmically transformed,
and the normal distribution test was conducted using one-sample
Kolmogorov–Smirnov test within-group in pharmacokinetic vari-
ables of levosulpiride except Tmax (using nonparametric tests). The
variables of levosulpiride were compared between the 25 mg dose
and 50 mg dose groups using paired samples t-test. To conﬁrm
whether Cmax and AUC0 t for levosulpiride were dose propor-
tional over the 25–50 mg dose range in healthy Chinese subjects,
paired samples t–test was performed in dose corrected data ln
(Cmax/dose) and ln (AUC0 t/dose). Body weight corrected
AUC0 t and Cmax and untransformed parameter values of both
sexes were compared using independent samples t-test to evaluate
gender difference. To compare pharmacokinetic parameter values
of 25 mg dose between single-dose study and multi-dose study,
paired samples t-test was used. One-way analysis of variance was
used to compare the lowest plasma concentrations on day 3–5.3. Results and discussion
3.1. Plasma assay
The plasma assay method was fully validated. Retention times of
levosulpiride and IS were 2.81 and 2.97 min, respectively.
Levosulpiride and the IS were baseline separated with symmetrical
narrow peaks. Standard curves for levosulpiride were linear over
the concentration range 2–2000 ng/mL with correlation coefﬁ-
cients (r2) 40.9995. Low (5 ng/mL), medium (300 ng/mL) and
high (1600 ng/mL) quality control (QC) samples for levosulpiride
were prepared. Within-run and between-run precisions of QC
samples were 5.3% and 8.0% (relative deviation %), respectively.
No carryover was observed in a blank plasma sample immediately
following an injection of the highest levosulpiride calibration
standard when the cycle was repeated four times. Matrix effect
(from 97.4% to 107.9%) and recovery (from 87.7% to 102.0%) of
QC samples at three levels (low, median, high) were sufﬁcient for
the analysis of levosulpiride in human plasma. Levosulpiride was
stable in plasma for 13 h at room temperature, 2 months at
20 1C, after three freeze–thaw cycles and in autosampler for
39 h at low and high QC levels.
3.2. Safety and tolerability
The most common adverse events reported during levosulpiride
treatment are dizziness, drowsiness and endocrine effects; rare
adverse events are cardiovascular and extrapyramidal effects4,18–19.
In our study, there were no serious adverse events like extrapyr-
amidal symptoms, and the only clinically signiﬁcant abnormality
was the mildly elevated serum alanine aminotransferase concen-
tration in two male volunteers. This adverse event started 13 h
after the last sample collection in multiple 25 mg dose study. Ten
days later, the two male volunteers were reexamined, and this
effect disappeared without any medication during this period. The
adverse event was not observed in female volunteers, and did not
couple with elevated aspartate aminotransferase. Thus, more
attention should be paid to patients with drinking habits and
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occurrence of adverse reactions following doses greater than
50 mg8,20–21. Sulpiride-treated patients with extrapyramidalFigure 2 Concentration–time proﬁles of levosulpiride after single
intramuscular doses of 25 mg (-□-) and 50 mg (-▲-) injections. Data
are mean7standard deviation, n¼12 (6 males and 6 females).
Figure 3 Concentration–time proﬁles of levosulpiride after multiple
intramuscular doses of 25 mg (-●-) injections every 12 h for 5 days.
Data are mean7standard deviation, n¼12 (6 males and 6 females).
Table 2 Levosulpiride pharmacokinetic parameters following single
Parameter Single-dose
25 mg 50 mg
Cmax (ng/mL) 4417134 82372
AUC0–36 (ng  h/mL) 17247304 34787
Tmax (h) 0.3770.08 0.4470
t1/2 (h) 7.071.0 6.870.
MRT0 t (h) 6.970.9 6.870.
CLz/F (L/h) 14.672.7 14.572
Vz/F (L) 146733 14372
Cav (ng/mL) – –
Cssmin (ng/mL) – –
AUC0τ (ng  h/mL) 13407247 –
AUCss (ng  h/mL) – –
R1 – –
R2 – –
DF – –
Data are from 6 male and 6 female volunteers and are given as mean7standa
25 mg dose and multiple 25 mg dose are listed with P values.
nPo0.05 means there is a statistical difference (95% conﬁdence intervaladverse events had signiﬁcantly higher drug concentrations in
serum8. All these clinical results suggested that adverse events are
associated with high doses and elevated plasma concentrations.
The doses in our study are much lower, consistent with the very
low incidence of adverse events. Overall, single-dose and multi-
dose im administration of levosulpiride were well tolerated by
healthy volunteers.
3.3. Single-dose pharmacokinetics
Fig. 2 shows the mean levosulpiride concentration–time proﬁles of
12 subjects after single 25 mg and 50 mg im administration. No
statistical differences were noted between the 25 and 50 mg single
dose results for the ln (Cmax/dose) or the ln (AUC0 t/dose)
parameters. Furthermore, values for Tmax, t1/2 and CLz/F were
independent of levosulpiride dose. Levosulpiride was absorbed
rapidly, with a Tmax less than 0.5 h after im administration,
consistent with the results from a previous study in Cauca-
sians10,15. The AUC after im injections of levosulpiride in our
study were much larger than those after oral administration of the
same levosulpiride dose in Korean volunteers16,22,23, but similar to
values after im administration of sulpiride in Caucasians10,14. The
Vz/F was 146733 L (25 mg dose study) and 143728 L (50 mg
dose study), suggesting that levosulpiride was widely distributed
all over the body or distributed largely in a speciﬁc tissue. The t1/2
of levosulpiride in Chinese volunteers after im administration was
about 7 h, which was consistent with that of enantiomers of
sulpiride in Caucasians10,14. The CLz/F was about 14.5 L/h in
our study.
3.4. Multi–dose pharmacokinetics
Fig. 3 reveals that after 25 mg im doses of levosulpiride every 12 h
for 5 consecutive days in 12 subjects, the mean Cmax increased
from 441 ng/mL (single 25 mg dose) to 539 ng/mL (Cssmax,
multiple 25 mg doses). The AUC0 t increased from 1340 ng  h/mL
(AUC0τ, single 25 mg dose) to 1635 ng  h/mL (AUCss, multiple-dose and multi-dose intramuscular studies.
Multi-dose on day 5 P value
25 mg
18 5397103 0.013*
585 21467449 0.000*
.14 0.3370.08 0.054
6 7.671.1 0.009*
8 7.170.7 0.083
.7 15.973.3 0.002*
8 174738 0.001*
136728 –
53.2712.8 –
– –
16357334 –
1.220 –
1.222 –
3.6070.47 –
rd deviation. The pharmacokinetic parameter differences between single
). –Not applicable.
Table 3 Gender differences following a single im dose of
25 mg levosulpiride.
Parameter Male Female P
Cmax (ng/mL) 3837135 4997116 0.446
Tmax (h) 0.3670.07 0.3970.10 0.589
AUC0–36 (ng  h/mL) 16717299 17787326 0.328
t1/2 (h) 7.670.8 6.370.8 0.021
*
MRT0 t (h) 7.570.8 6.370.5 0.011
*
CLz/F (L/h) 14.972.8 14.372.8 0.696
Vz/F (L) 163732 130727 0.082
Body weight corrected Cmax, AUC0–36 and the other parameters in
the table were compared between genders. The data come from 6
male and 6 female volunteers and are given as mean7standard
deviation. The P values are listed and
nPo0.05 means there is a statistical difference (95% conﬁdence
interval).
Figure 4 Elimination half-life of levosulpiride in 12 healthy Chinese
volunteers (6 males and 6 females) after intramuscular administration
of single 25 mg dose (study 1), single 50 mg dose (study 2) and
multiple 25 mg doses (study 3) levosulpiride injections.
C. Gong et al.40625 mg doses). Consistent with the single–dose data, Tmax was
2075 min. Compared with the results at single dose studies, the
Vz/F was increased by 19.2%, the t1/2 was increased by 8.6%, and the
CLz/F was increased by 8.9% at steady state. These differences were
about 10% and were smaller than the experimental errors. Thus, they
can be ignored. The accumulation ratios expressed as AUCss/
AUC0τ (R1) and Cssmax/Cmax (R2) were 1.220 and 1.222. The drug
was almost completely eliminated 36 h after the last dose. Plasma
concentrations at steady state before morning injections on day 3, 4, 5
showed no signiﬁcant differences among the three days, meaning
steady state was achieved within 48 h. The DF was 3.6070.47. In
the present study, inter-individual pharmacokinetic variability (eval-
uated as the coefﬁcient of variation of the pharmacokinetic para-
meters) was 10% and 30% (average 20%). These results show that
after im administration of 25 mg levosulpiride every 12 h, steady state
is reached after two days. Multiple doses of levosulpiride increased
the drug exposure by 22%. The levosulpiride pharmacokinetic
parameters after single-dose and multi-dose studies are shown in
Table 2.3.5. Gender differences in pharmacokinetics
Gender differences of pharmacokinetics were evaluated in six
males and six females for single-dose and multi-dose studies. The
results are displayed in Table 3. In the single 25 mg dose study,
the mean t1/2 was 17% smaller (Fig. 4), and the Vz/F was 20%
smaller in females than in males. Earlier reports of the pharma-
cokinetics of sulpiride14 found that the disposition rate of drug in
male is slightly slower than in female Caucasians after iv
administration. These gender differences are similar to the results
in the single 50 mg dose and the multi-dose studies.4. Conclusions
Our ﬁndings showed that after im administration of levosulpiride
in healthy Chinese volunteers, Cmax and AUC0 t for levosulpiride
were dose proportional over the 25–50 mg dose range, and steady
state was reached within 2 days after im administration of 25 mg
dose every 12 h. There was a slight accumulation of drug at steady
state, but the drug was almost completely eliminated 36 h after the
last dose. These results showed that im administration of levo-
sulpiride was well tolerated by healthy Chinese volunteers.References
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